pfizer oral glp-1 to discontinue danuglipron, its pill for obesity| STAT Pfizer, Novo Nordisk bidding war

According to the 2024 World Obesity Report, the global prevalence of obesity is steadily increasing, with projections indicating that by 2035, over half of the world's population will be classified as overweight [1]

Learn about effective dosages, FDA safety guidelines, individual response factors, and how allulose compares to pharmaceutical GLP-1 medications for blood sugar control.

Additionally, these routine blood tests can help your prescriber (and you!) determine the effectiveness of the medication, offering valuable insights into whether dosing adjustments or supplementary treatments are required

Wondering How Overweight You Need to Be for Ozempic

Companies operating in this space may benefit from reviewing their promotional materials to ensure alignment with FDA expectations

Does Wegovy cause heart palpitations